Definitive Contract HHSN261201300073C

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

This is a federal contract award by the National Cancer Institute, a civilian agency, to Vignet Inc., a minority-owned, woman-owned small business. The contract is for research and development in the medical/biomedical field, with a ceiling value of $1,386,076.38 and a period of performance ending on December 31, 2019. The contract type is a cost-plus-fixed-fee definitive contract, with no set-aside designation. Based on the agency and contract description, this award is likely part of the...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&amp;D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&amp;D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...

<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>

This is a $182,050 firm fixed price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nanoivd, Inc., a small disadvantaged, woman-owned business. The contract is for TAS::75 0849::TAS and has a total small business set-aside designation. The period of performance runs from the award date of September 30, 2010 through the ultimate completion date of March 30, 2011. Nanoivd, Inc. is the prime contractor, and no subcontractors are mentioned. The contract...

This is a federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pointcare Genomics Corp, a small minority-owned business, for research and development in biomedical basic research. The contract is a definitive, firm-fixed price contract valued at $299,961.00 and is part of the SBIR (Small Business Innovation Research) Program Phase I. The contract has a total small business set-aside designation and was awarded on September 22, 2015, with a completion date of...

<p>This is a definitive, firm fixed-price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Benevir Biopharm, Inc., a small business, for R&amp;D medical/biomedical services. The contract has a ceiling value of $199,904.00 and a completion date of February 12, 2014. The contract was set aside for small businesses.</p>

This is a $189,094.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Angiocrine Bioscience, Inc., a for-profit organization. The contract is for the &quot;SBIR PHASE I LARGE SCALE PROPAGATION OF CANCER CELLS USING THE VERAVEC PLATFORM IN AN AUTOMATED CLOSED SYSTEM&quot; and was set aside for small businesses. The contract has an ultimate completion date of July 21, 2016 and was awarded on September 22, 2015. This appears to be a Small Business...

<p>This is a $994,198.78 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Precision For Medicine (TX), Inc. on September 20, 2013. The contract is for research and development in biomedical (basic research) and has a period of performance through September 19, 2015. The contract is designated as a total small business set-aside.</p>

<p>This is a $150,000 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Bioptix Diagnostics, Inc., a for-profit manufacturer. The contract is for Phase I of a Small Business Innovation Research (SBIR) project under Topic 281. The contract has a completion date of June 29, 2011. As an SBIR award, this contract was set aside for small businesses.</p>